Ilyang PharmaceuticalLtd Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Dong-Yeon Kim
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | 0.05% |
| Management average tenure | no data |
| Board average tenure | no data |
Recent management updates
Recent updates
Ilyang Pharmaceutical Co.,Ltd's (KRX:007570) 28% Price Boost Is Out Of Tune With Revenues
Jan 06
Here's Why Ilyang PharmaceuticalLtd (KRX:007570) Has A Meaningful Debt Burden
Jan 03Is Ilyang PharmaceuticalLtd (KRX:007570) A Risky Investment?
Apr 04Should You Be Adding Ilyang PharmaceuticalLtd (KRX:007570) To Your Watchlist Today?
Mar 14Ilyang Pharmaceutical Co.,Ltd (KRX:007570) Shares May Have Slumped 36% But Getting In Cheap Is Still Unlikely
Mar 14Declining Stock and Decent Financials: Is The Market Wrong About Ilyang Pharmaceutical Co.,Ltd (KRX:007570)?
Feb 22Did Business Growth Power Ilyang PharmaceuticalLtd's (KRX:007570) Share Price Gain of 159%?
Feb 01Is Ilyang Pharmaceutical Co.,Ltd's (KRX:007570) Shareholder Ownership Skewed Towards Insiders?
Jan 11
Here's Why Ilyang PharmaceuticalLtd (KRX:007570) Can Manage Its Debt Responsibly
Dec 24A Look At The Intrinsic Value Of Ilyang Pharmaceutical Co.,Ltd (KRX:007570)
Dec 06Ilyang Pharmaceutical Co.,Ltd (KRX:007570) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Nov 18CEO
Dong-Yeon Kim (74 yo)
no data
Tenure
Mr. Dong-Yeon Kim serves as the Chief Executive Officer and President of Ilyang Pharmaceutical Co., Ltd. Mr. Kim served as Head of Laboratory at Ilyang Pharmaceutical Co., Ltd. He serves as a Director of I...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/17 03:08 |
| End of Day Share Price | 2025/02/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ilyang Pharmaceutical Co.,Ltd is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyung Soo Kim | Cape Investment & Securities Co., Ltd. |
| Jae Hoon Shin | LS Securities Co., Ltd. |
| Jaechul Park | Mirae Asset Securities Co., Ltd. (Pre-Merger) |